Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer.
about
Variation in neoadjuvant chemotherapy utilization for epithelial ovarian cancer at high volume hospitals in the United States and associated survival.Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy?Neoadjuvant chemotherapy versus primary debulking surgery in advanced epithelial ovarian cancer: A meta-analysis of peri-operative outcome.Cost effectiveness of neoadjuvant chemotherapy followed by interval cytoreductive surgery versus primary cytoreductive surgery for patients with advanced stage ovarian cancer during the initial treatment phase.Lymph node metastases as only qualifier for stage IV serous ovarian cancer confers longer survival than other sites of distant disease - a Swedish Gynecologic Cancer Group (SweGCG) study.Progress in the management of primary and recurrent ovarian carcinomatosis with peritonectomy procedure and HIPEC in a high volume centre.Effect of adoption of neoadjuvant chemotherapy for advanced ovarian cancer on all cause mortality: quasi-experimental study.OV21/PETROC: A randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer.The role of neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer: a systematic review and meta-analysis of randomized controlled trials and observational studies.A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience.Imaging and therapy of ovarian cancer: clinical application of nanoparticles and future perspectives
P2860
Q38861953-B4504A13-4D80-498F-ACBB-52104AB27123Q38941559-08F53C71-62B2-4C67-A056-465B9694AB54Q43011510-C4B4EEF3-2CC4-4815-8B4A-63711ECB2023Q47257079-1FAF403F-99E6-486E-8043-F783B305A925Q48318844-7005075F-CCE1-4409-97C1-C346334765FAQ48794449-DA4C1878-B971-4B1C-B8DE-E94C4E00DB94Q49337608-FDB90744-740B-4169-8A9C-A1634A4A28D3Q49550401-A1B90705-F500-4161-9566-A2360B27054AQ55008645-39E84606-1650-426E-B9A3-3DF078D7095BQ55302464-8470CF41-3E08-4E95-84A4-6B1D1DFE629DQ57174233-3F0E9802-D532-42E9-A6C0-17076992591E
P2860
Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer.
description
2016 nî lūn-bûn
@nan
2016 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer.
@ast
Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer.
@en
type
label
Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer.
@ast
Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer.
@en
prefLabel
Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer.
@ast
Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer.
@en
P2093
P2860
P356
P1476
Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer.
@en
P2093
Alexi A Wright
Angel M Cronin
Charles F Levenback
Charlotte C Sun
David M O'Malley
Gina Mantia-Smaldone
Jennifer J Griggs
Joyce C Niland
Kristin Bixel
Larissa A Meyer
P2860
P356
10.1200/JCO.2016.68.1239
P407
P577
2016-09-06T00:00:00Z